IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19

Literature Cited

1. 1. 

   Kishimoto T, Ishizaka K. 1973. Regulation of antibody response in vitro: VII. Enhancing soluble factors for IgG and IgE antibody response. J. Immunol. 111:1194–205
   [Google Scholar]
2. 2. 

   Kishimoto T, Ishizaka K. 1973. Regulation of antibody response in vitro: VI. Carrier-specific helper cells for IgG and IgE antibody response. J. Immunol. 111:720–32
   [Google Scholar]
3. 3. 

   Kishimoto T, Ishizaka K. 1973. Regulation of antibody response in vitro: V. Effect of carrier-specific helper cells on generation of hapten-specific memory cells of different immunoglobulin classes. J. Immunol. 111:1–9
   [Google Scholar]
4. 4. 

   Kang S, Narazaki M, Metwally H, Kishimoto T. 2020. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 217:e20190347 Erratum 2020. J. Exp. Med. 217:5jem.2019034704212020c
   [Google Scholar]
5. 5. 

   Kang S, Tanaka T, Narazaki M, Kishimoto T 2019. Targeting interleukin-6 signaling in clinic. Immunity 50:1007–23
   [Google Scholar]
6. 6. 

   Hirano T, Kuritani T, Kishimoto T, Yamamura Y 1977. In vitro immune response of human peripheral lymphocytes: I. The mechanism(s) involved in T cell helper functions in the pokeweed mitogen-induced differentiation and proliferation of B cells. J. Immunol. 119:1235–41
   [Google Scholar]
7. 7. 

   Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K et al. 1982. Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J. Exp. Med. 155:914–23
   [Google Scholar]
8. 8. 

   Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y et al. 1986. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73–76
   [Google Scholar]
9. 9. 

   Kishimoto T. 1989. The biology of interleukin-6. Blood 74:1–10
   [Google Scholar]
10. 10. 

    Tanabe O, Akira S, Kamiya T, Wong GG, Hirano T, Kishimoto T. 1988. Genomic structure of the murine IL-6 gene: high degree conservation of potential regulatory sequences between mouse and human. J. Immunol. 141:3875–81
    [Google Scholar]
11. 11. 

    Kaur S, Bansal Y, Kumar R, Bansal G. 2020. A panoramic review of IL-6: structure, pathophysiological roles and inhibitors. Bioorg. Med. Chem. 28:115327
    [Google Scholar]
12. 12. 

    Yawata H, Yasukawa K, Natsuka S, Murakami M, Yamasaki K et al. 1993. Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO J 12:1705–12
    [Google Scholar]
13. 13. 

    Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T 1990. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149–57
    [Google Scholar]
14. 14. 

    Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K et al. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573–81
    [Google Scholar]
15. 15. 

    Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y et al. 1988. Cloning and expression of the human interleukin-6 (BSF-2/IFNβ 2) receptor. Science 241:825–28
    [Google Scholar]
16. 16. 

    Hunter CA, Jones SA. 2015. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16:448–57
    [Google Scholar]
17. 17. 

    Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. 1992. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4:96–100
    [Google Scholar]
18. 18. 

    Heink S, Yogev N, Garbers C, Herwerth M, Aly L et al. 2017. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic T_H17 cells. Nat. Immunol. 18:74–85 Erratum 2017. Nat. Immunol. 18:474
    [Google Scholar]
19. 19. 

    Garbers C, Heink S, Korn T, Rose-John S. 2018. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat. Rev. Drug Discov. 17:395–412
    [Google Scholar]
20. 20. 

    Jones SA, Jenkins BJ. 2018. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18:773–89
    [Google Scholar]
21. 21. 

    Rose-John S. 2017. The soluble interleukin 6 receptor: advanced therapeutic options in inflammation. Clin. Pharmacol. Ther. 102:591–98
    [Google Scholar]
22. 22. 

    Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S et al. 1990. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 9:1897–906
    [Google Scholar]
23. 23. 

    Akira S, Nishio Y, Inoue M, Wang XJ, Wei S et al. 1994. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77:63–71
    [Google Scholar]
24. 24. 

    Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S et al. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924–29
    [Google Scholar]
25. 25. 

    Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334:Part 2297–314
    [Google Scholar]
26. 26. 

    Hibi M, Hirano T. 2000. Gab-family adapter molecules in signal transduction of cytokine and growth factor receptors, and T and B cell antigen receptors. Leuk. Lymphoma 37:299–307
    [Google Scholar]
27. 27. 

    Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE Jr., Yancopoulos GD. 1995. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267:1349–53
    [Google Scholar]
28. 28. 

    Ait-Ghezala G, Volmar CH, Frieling J, Paris D, Tweed M et al. 2007. CD40 promotion of amyloid beta production occurs via the NF-κB pathway. Eur. J. Neurosci. 25:1685–95
    [Google Scholar]
29. 29. 

    Taniguchi K, Moroishi T, de Jong PR, Krawczyk M, Grebbin BM et al. 2017. YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. PNAS 114:1643–48
    [Google Scholar]
30. 30. 

    Heinrich PC, Castell JV, Andus T. 1990. Interleukin-6 and the acute phase response. Biochem. J. 265:621–36
    [Google Scholar]
31. 31. 

    Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R. 2000. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32:49–55
    [Google Scholar]
32. 32. 

    Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S et al. 2004. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 113:1271–76
    [Google Scholar]
33. 33. 

    Obici L, Perfetti V, Palladini G, Moratti R, Merlini G 2005. Clinical aspects of systemic amyloid diseases. Biochim. Biophys. Acta Proteins Proteom. 1753:11–22
    [Google Scholar]
34. 34. 

    Peters M, Blinn G, Jostock T, Schirmacher P, Meyer zum Buschenfelde KH et al. 2000. Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 119:1663–71
    [Google Scholar]
35. 35. 

    Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE et al. 1996. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274:1379–83
    [Google Scholar]
36. 36. 

    Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM et al. 2013. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 144:1530–42.e12
    [Google Scholar]
37. 37. 

    Wong VW, Yu J, Cheng AS, Wong GL, Chan HY et al. 2009. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int. J. Cancer 124:2766–70
    [Google Scholar]
38. 38. 

    Kawano M, Hirano T, Matsuda T, Taga T, Horii Y et al. 1988. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85
    [Google Scholar]
39. 39. 

    Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S et al. 2011. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. PNAS 108:3701–6
    [Google Scholar]
40. 40. 

    Bettelli E, Carrier Y, Gao W, Korn T, Strom TB et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector T_H17 and regulatory T cells. Nature 441:235–38
    [Google Scholar]
41. 41. 

    Kimura A, Kishimoto T. 2010. IL-6: regulator of Treg/Th17 balance. Eur. J. Immunol. 40:1830–35
    [Google Scholar]
42. 42. 

    Liao W, Lin JX, Wang L, Li P, Leonard WJ 2011. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat. Immunol. 12:551–59
    [Google Scholar]
43. 43. 

    Ma CS, Deenick EK, Batten M, Tangye SG. 2012. The origins, function, and regulation of T follicular helper cells. J. Exp. Med. 209:1241–53
    [Google Scholar]
44. 44. 

    Harker JA, Lewis GM, Mack L, Zuniga EI 2011. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334:825–29
    [Google Scholar]
45. 45. 

    Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. 1988. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol. 141:1543–49
    [Google Scholar]
46. 46. 

    Hashizume M, Hayakawa N, Mihara M. 2008. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology 47:1635–40
    [Google Scholar]
47. 47. 

    De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R et al. 2006. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 54:3551–63
    [Google Scholar]
48. 48. 

    Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T et al. 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521–29
    [Google Scholar]
49. 49. 

    Poplutz MK, Wessels I, Rink L, Uciechowski P. 2014. Regulation of the interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation. Immunobiology 219:619–26
    [Google Scholar]
50. 50. 

    Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS et al. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Investig. 102:1369–76
    [Google Scholar]
51. 51. 

    Hou H, Wang C, Sun F, Zhao L, Dun A, Sun Z 2015. Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis. Inflamm. Res. 64:707–20
    [Google Scholar]
52. 52. 

    Akira S, Kishimoto T 1992. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol. Rev. 127:25–50
    [Google Scholar]
53. 53. 

    Akira S. 1997. IL-6-regulated transcription factors. Int. J. Biochem. Cell Biol. 29:1401–18
    [Google Scholar]
54. 54. 

    Ballard DW, Bohnlein E, Lowenthal JW, Wano Y, Franza BR, Greene WC. 1988. HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science 241:1652–55
    [Google Scholar]
55. 55. 

    Scala G, Ruocco MR, Ambrosino C, Mallardo M, Giordano V et al. 1994. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J. Exp. Med. 179:961–71
    [Google Scholar]
56. 56. 

    Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM et al. 1999. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J. Biol. Chem. 274:32048–54
    [Google Scholar]
57. 57. 

    Kimura A, Naka T, Nakahama T, Chinen I, Masuda K et al. 2009. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J. Exp. Med. 206:2027–35
    [Google Scholar]
58. 58. 

    Nakahama T, Kimura A, Nguyen NT, Chinen I, Hanieh H et al. 2011. Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis. PNAS 108:14222–27
    [Google Scholar]
59. 59. 

    Chen CY, Chang JT, Ho YF, Shyu AB. 2016. MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by silencing HMGA1 and MALT1. Nucleic Acids Res 44:3772–87
    [Google Scholar]
60. 60. 

    He M, Xu Z, Ding T, Kuang DM, Zheng L. 2009. microRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPβ. Cell Mol. Immunol. 6:343–52
    [Google Scholar]
61. 61. 

    Song Q, Li H, Shao H, Li C, Lu X 2015. microRNA-365 in macrophages regulates Mycobacterium tuberculosis-induced active pulmonary tuberculosis via interleukin-6. Int. J. Clin. Exp. Med. 8:15458–65
    [Google Scholar]
62. 62. 

    Iwasaki H, Takeuchi O, Teraguchi S, Matsushita K, Uehata T et al. 2011. The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat. Immunol. 12:1167–75
    [Google Scholar]
63. 63. 

    Matsushita K, Takeuchi O, Standley DM, Kumagai Y, Kawagoe T et al. 2009. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458:1185–90
    [Google Scholar]
64. 64. 

    Mino T, Takeuchi O. 2018. Post-transcriptional regulation of immune responses by RNA binding proteins. Proc. Jpn. Acad. Ser. B 94:248–58
    [Google Scholar]
65. 65. 

    Mino T, Murakawa Y, Fukao A, Vandenbon A, Wessels HH et al. 2015. Regnase-1 and roquin regulate a common element in inflammatory mRNAs by spatiotemporally distinct mechanisms. Cell 161:1058–73
    [Google Scholar]
66. 66. 

    Masuda K, Ripley B, Nishimura R, Mino T, Takeuchi O et al. 2013. Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. PNAS 110:9409–14
    [Google Scholar]
67. 67. 

    Masuda K, Ripley B, Nyati KK, Dubey PK, Zaman MM et al. 2016. Arid5a regulates naive CD4⁺ T cell fate through selective stabilization of Stat3 mRNA. J. Exp. Med. 213:605–19
    [Google Scholar]
68. 68. 

    Saito Y, Kagami S, Sanayama Y, Ikeda K, Suto A et al. 2014. AT-rich-interactive domain-containing protein 5A functions as a negative regulator of retinoic acid receptor-related orphan nuclear receptor γt-induced Th17 cell differentiation. Arthritis Rheum 66:1185–94
    [Google Scholar]
69. 69. 

    Ferreira MA, Matheson MC, Duffy DL, Marks GB, Hui J et al. 2011. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet 378:1006–14
    [Google Scholar]
70. 70. 

    Hawkins GA, Robinson MB, Hastie AT, Li X, Li H et al. 2012. The IL6R variation Asp³⁵⁸Ala is a potential modifier of lung function in subjects with asthma. J. Allergy Clin. Immunol. 130:510–15.e1
    [Google Scholar]
71. 71. 

    Garbers C, Monhasery N, Aparicio-Siegmund S, Lokau J, Baran P et al. 2014. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim. Biophys. Acta Mol. Basis Dis. 1842:1485–94
    [Google Scholar]
72. 72. 

    Aparicio-Siegmund S, Garbers Y, Flynn CM, Waetzig GH, Gouni-Berthold I et al. 2019. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 317:E411–20
    [Google Scholar]
73. 73. 

    Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U et al. 1998. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J. Immunol. 161:6347–55
    [Google Scholar]
74. 74. 

    Schwerd T, Twigg SRF, Aschenbrenner D, Manrique S, Miller KA et al. 2017. A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis. J. Exp. Med. 214:2547–62
    [Google Scholar]
75. 75. 

    Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC et al. 1999. Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder. N. Engl. J. Med. 340:692–702
    [Google Scholar]
76. 76. 

    Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H et al. 2007. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448:1058–62
    [Google Scholar]
77. 77. 

    Spencer S, Köstel Bal S, Egner W, Lango Allen H, Raza SI et al. 2019. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J. Exp. Med. 216:91986–98
    [Google Scholar]
78. 78. 

    Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ et al. 2003. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33:388–91
    [Google Scholar]
79. 79. 

    Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM et al. 2011. Inflammatory skin and bowel disease linked to ADAM17 deletion. N. Engl. J. Med. 365:1502–8
    [Google Scholar]
80. 80. 

    Kreins AY, Ciancanelli MJ, Okada S, Kong XF, Ramirez-Alejo N et al. 2015. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 212:1641–62
    [Google Scholar]
81. 81. 

    Kang S, Tanaka T, Kishimoto T. 2015. Therapeutic uses of anti-interleukin-6 receptor antibody. Int. Immunol. 27:21–29
    [Google Scholar]
82. 82. 

    Lamertz L, Rummel F, Polz R, Baran P, Hansen S et al. 2018. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses. Sci. Signal. 11:eaar7388
    [Google Scholar]
83. 83. 

    Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H et al. 1993. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82:1120–26
    [Google Scholar]
84. 84. 

    Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. 1992. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J. Rheumatol. 19:22–25
    [Google Scholar]
85. 85. 

    Gabay C. 2006. Interleukin-6 and chronic inflammation. Arthritis Res. Ther. 8:Suppl. 2S3
    [Google Scholar]
86. 86. 

    Hein GE, Kohler M, Oelzner P, Stein G, Franke S. 2005. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol. Int. 26:137–41
    [Google Scholar]
87. 87. 

    Kishimoto T. 2005. Interleukin-6: from basic science to medicine—40 years in immunology. Annu. Rev. Immunol. 23:1–21
    [Google Scholar]
88. 88. 

    Lally F, Smith E, Filer A, Stone MA, Shaw JS et al. 2005. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum 52:3460–69
    [Google Scholar]
89. 89. 

    Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C 2003. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 24:25–29
    [Google Scholar]
90. 90. 

    Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M 1989. Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. J. Clin. Investig. 83:585–92
    [Google Scholar]
91. 91. 

    Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC et al. 1992. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257:88–91
    [Google Scholar]
92. 92. 

    Poli V, Balena R, Fattori E, Markatos A, Yamamoto M et al. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189–96
    [Google Scholar]
93. 93. 

    Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K et al. 1998. Interleukin 6 plays a key role in the development of antigen-induced arthritis. PNAS 95:8222–26
    [Google Scholar]
94. 94. 

    Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K et al. 1998. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41:2117–21
    [Google Scholar]
95. 95. 

    Wendling D, Racadot E, Wijdenes J 1993. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20:259–62
    [Google Scholar]
96. 96. 

    Nishimoto N, Kishimoto T, Yoshizaki K. 2000. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann. Rheum. Dis. 59:Suppl. 1i21–27
    [Google Scholar]
97. 97. 

    Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y et al. 2002. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46:3143–50
    [Google Scholar]
98. 98. 

    Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J et al. 2006. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–29
    [Google Scholar]
99. 99. 

    Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S et al. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761–69
    [Google Scholar]
100. 100. 

     Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A et al. 2010. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69:88–96
     [Google Scholar]
101. 101. 

     Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R et al. 2013. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541–50
     [Google Scholar]
102. 102. 

     Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R et al. 2015. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheum 67:1424–37
     [Google Scholar]
103. 103. 

     Ravelli A, Martini A. 2007. Juvenile idiopathic arthritis. Lancet 369:767–78
     [Google Scholar]
104. 104. 

     De Benedetti F, Pignatti P, Gerloni V, Massa M, Sartirana P et al. 1997. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J. Rheumatol. 24:1403–9
     [Google Scholar]
105. 105. 

     Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S et al. 2005. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52:818–25
     [Google Scholar]
106. 106. 

     De Benedetti F, Brunner H, Ruperto N, Schneider R, Xavier R et al. 2015. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheum 67:840–48
     [Google Scholar]
107. 107. 

     Miyamae T, Yokoya S, Yamanaka H, Yokota S 2014. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy. Mod. Rheumatol. 24:567–71
     [Google Scholar]
108. 108. 

     Fautrel B. 2008. Adult-onset Still disease. Best Pract. Res. Clin. Rheumatol. 22:773–92
     [Google Scholar]
109. 109. 

     Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K et al. 2018. Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann. Rheum. Dis. 77:1720–29
     [Google Scholar]
110. 110. 

     Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L et al. 1989. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74:1360–67
     [Google Scholar]
111. 111. 

     Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. 1990. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Investig. 86:592–99
     [Google Scholar]
112. 112. 

     Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W et al. 2012. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 119:5173–81
     [Google Scholar]
113. 113. 

     Mori Y, Nishimoto N, Ohno M, Inagi R, Dhepakson P et al. 2000. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. J. Med. Virol. 61:332–35
     [Google Scholar]
114. 114. 

     Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M et al. 2005. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–32
     [Google Scholar]
115. 115. 

     Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T et al. 2000. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56–61
     [Google Scholar]
116. 116. 

     Dasgupta B, Panayi GS. 1990. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br. J. Rheumatol. 29:456–58
     [Google Scholar]
117. 117. 

     Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G 1999. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions?. Circulation 100:55–60
     [Google Scholar]
118. 118. 

     Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M et al. 2017. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377:317–28
     [Google Scholar]
119. 119. 

     Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T et al. 2018. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann. Rheum. Dis. 77:348–54
     [Google Scholar]
120. 120. 

     Jarius S, Wildemann B 2010. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat. Rev. Neurol. 6:383–92
     [Google Scholar]
121. 121. 

     Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. 2007. The spectrum of neuromyelitis optica. Lancet Neurol 6:805–15
     [Google Scholar]
122. 122. 

     Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T et al. 2014. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82:1302–6
     [Google Scholar]
123. 123. 

     Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E et al. 2020. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19:402–12
     [Google Scholar]
124. 124. 

     Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B et al. 2019. Trial of satralizumab in neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381:2114–24
     [Google Scholar]
125. 125. 

     Tanaka T, Narazaki M, Kishimoto T. 2014. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6:a016295
     [Google Scholar]
126. 126. 

     Akira S, Taga T, Kishimoto T. 1993. Interleukin-6 in biology and medicine. Adv. Immunol. 54:1–78
     [Google Scholar]
127. 127. 

     Akira S, Takeda K. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499–511
     [Google Scholar]
128. 128. 

     Piccinini AM, Midwood KS. 2010. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010:672395
     [Google Scholar]
129. 129. 

     Tanaka T, Narazaki M, Kishimoto T. 2016. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8:959–70
     [Google Scholar]
130. 130. 

     Levi M, ten Cate H. 1999. Disseminated intravascular coagulation. N. Engl. J. Med. 341:586–92
     [Google Scholar]
131. 131. 

     Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA et al. 1999. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718–23
     [Google Scholar]
132. 132. 

     Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S et al. 2020. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. PNAS 117:22351–56
     [Google Scholar]
133. 133. 

     Marin V, Montero-Julian FA, Gres S, Boulay V, Bongrand P et al. 2001. The IL-6-soluble IL-6Rα autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J. Immunol. 167:3435–42
     [Google Scholar]
134. 134. 

     Jirik FR, Podor TJ, Hirano T, Kishimoto T, Loskutoff DJ et al. 1989. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J. Immunol. 142:144–47
     [Google Scholar]
135. 135. 

     Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P et al. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315–25
     [Google Scholar]
136. 136. 

     Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. 1996. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271:736–41
     [Google Scholar]
137. 137. 

     Desai TR, Leeper NJ, Hynes KL, Gewertz BL. 2002. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J. Surg. Res. 104:118–23
     [Google Scholar]
138. 138. 

     Esser S, Lampugnani MG, Corada M, Dejana E, Risau W 1998. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 111:Part 131853–65
     [Google Scholar]
139. 139. 

     Laudes IJ, Chu JC, Huber-Lang M, Guo RF, Riedemann NC et al. 2002. Expression and function of C5a receptor in mouse microvascular endothelial cells. J. Immunol. 169:5962–70
     [Google Scholar]
140. 140. 

     Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ et al. 2003. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 170:503–7
     [Google Scholar]
141. 141. 

     Finkel MS, Romeo RC, Oddis CV, Salama G. 1992. Inotropic effects of calcium antagonists in the cardiomyopathic Syrian hamster. J. Cardiovasc. Pharmacol. 19:546–53
     [Google Scholar]
142. 142. 

     Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC et al. 2004. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 363:203–9
     [Google Scholar]
143. 143. 

     Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA et al. 2015. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7:303ra139
     [Google Scholar]
144. 144. 

     Matthys P, Dillen C, Proost P, Heremans H, Van Damme J, Billiau A. 1993. Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur. J. Immunol. 23:2209–16
     [Google Scholar]
145. 145. 

     Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. 2018. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24:731–38
     [Google Scholar]
146. 146. 

     Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A et al. 2018. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24:739–48
     [Google Scholar]
147. 147. 

     Brentjens RJ, Davila ML, Riviere I, Park J, Wang X et al. 2013. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5:177ra38
     [Google Scholar]
148. 148. 

     Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM et al. 2013. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121:5154–57
     [Google Scholar]
149. 149. 

     van der Stegen SJ, Davies DM, Wilkie S, Foster J, Sosabowski JK et al. 2013. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?. J. Immunol. 191:4589–98
     [Google Scholar]
150. 150. 

     Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL et al. 2016. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6:664–79
     [Google Scholar]
151. 151. 

     Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL et al. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368:1509–18
     [Google Scholar]
152. 152. 

     Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM et al. 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371:1507–17
     [Google Scholar]
153. 153. 

     Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH et al. 2017. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood 130:2569–72
     [Google Scholar]
154. 154. 

     Gust J, Hay KA, Hanafi LA, Li D, Myerson D et al. 2017. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7:1404–19
     [Google Scholar]
155. 155. 

     Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. 1999. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217–24
     [Google Scholar]
156. 156. 

     Huang C, Wang Y, Li X, Ren L, Zhao J et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506
     [Google Scholar]
157. 157. 

     Moore JB, June CH. 2020. Cytokine release syndrome in severe COVID-19. Science 368:473–74
     [Google Scholar]
158. 158. 

     Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. 2020. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–34
     [Google Scholar]
159. 159. 

     Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R et al. 2020. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395:1417–18
     [Google Scholar]
160. 160. 

     Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ et al. 2020. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382:1708–20
     [Google Scholar]
161. 161. 

     Wu C, Chen X, Cai Y, Xia J, Zhou X et al. 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180:7934–43
     [Google Scholar]
162. 162. 

     Zhou F, Yu T, Du R, Fan G, Liu Y et al. 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–62
     [Google Scholar]
163. 163. 

     Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H et al. 2020. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 7:e575–82
     [Google Scholar]
164. 164. 

     Pine AB, Meizlish ML, Goshua G, Chang C-H, Zhang H et al. 2020. Circulating markers of angiogenesis and endotheliopathy in COVID-19. Pulm. Circ. 10:2045894020966547
     [Google Scholar]
165. 165. 

     Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M et al. 2020. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J. Thromb. Haemost. 18:1747–51
     [Google Scholar]
166. 166. 

     RECOVERY Collab. Group Horby P, Lim WS, Emberson JR, Mafham M et al. 2021. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384693–704
167. 167. 

     Xu X, Han M, Li T, Sun W, Wang D et al. 2020. Effective treatment of severe COVID-19 patients with tocilizumab. PNAS 117:10970–75
     [Google Scholar]
168. 168. 

     Biran N, Ip A, Ahn J, Go RC, Wang S et al. 2020. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol 2:e603–12
     [Google Scholar]
169. 169. 

     Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R et al. 2020. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2:e474–84
     [Google Scholar]
170. 170. 

     Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN et al. 2021. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin. Infect. Dis. 73:2e445–54
     [Google Scholar]
171. 171. 

     Salama C, Han J, Yau L, Reiss WG, Kramer B et al. 2021. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 384:20–30
     [Google Scholar]
172. 172. 

     Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD et al. (REMAP-CAP Investig.) 2021. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384:1491–502
     [Google Scholar]
173. 173. 

     Horby PW, Campbell M, Staplin N, Spata E, Emberson JR et al. (RECOVERY Collab. Group). 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397:1637–45
     [Google Scholar]
174. 174. 

     Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT et al. (WHO Rapid Evid. Apprais. COVID-19 Ther. Work. Group). 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 326:6499–518
     [Google Scholar]
175. 175. 

     Kishimoto T. 1985. Factors affecting B-cell growth and differentiation. Annu. Rev. Immunol. 3:133–57
     [Google Scholar]